Abstract
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the production of multiple autoantibodies and frequent renal involvement, known as lupus nephritis (LN). The precise mechanisms driving LN development remain poorly understood. Bacterial biofilms, which protect bacteria from environmental stressors, are ubiquitous. This study identifies a conserved peptide (HU1) derived from DNABII proteins—a major component of bacterial biofilms—that is specifically recognized by the sera of approximately 47% of SLE patients. Serum anti-HU1 levels significantly correlate with the occurrence of LN. In a pristane-induced mouse model, the presence of anti-HU1 antibodies aggravated lupus nephritis, despite these antibodies also attenuating biofilm formation. Further investigation revealed that anti-HU1 antibodies cross-recognize protein disulfide isomerase (P4HB) on the renal cell surface, inhibiting its enzymatic activity. These findings uncover a novel mechanism of LN development triggered by molecular mimicry of bacterial biofilm components.
Introduction
Systemic lupus erythematosus (SLE) is a complex autoimmune condition where the immune system targets the body's own tissues. Lupus Nephritis (LN) is one of its most severe complications, leading to significant kidney inflammation and potential failure. While environmental triggers like bacterial infections are known to cause disease "flares," the specific molecular links between common infections and kidney injury have been unclear.
Bacteria often exist within biofilms—slimy, protective matrices that confer resistance to antibiotics and immune clearance. This research investigates whether conserved proteins within these biofilms act as "decoys," inducing the production of autoantibodies that mistakenly attack the host’s kidneys through molecular mimicry.
Methods and Materials
The researchers utilized a multi-disciplinary approach to link bacterial components to human pathology. They first identified highly conserved regions within the DNABII protein family, which is present in nearly all eubacteria. Using sequence alignment, they synthesized two specific peptides: HU1 and HU2.
The study involved a human serum cohort consisting of 103 SLE patients, 136 Rheumatoid Arthritis (RA) patients, 133 primary Systemic Sclerosis (pSS) patients, and 150 healthy controls (HC). Specific antibodies were detected using ELISA. To study the disease in vivo, a pristane-induced mouse model of SLE was employed, where mice were immunized with the HU1 peptide to observe its impact on renal outcomes. Molecular targets were identified using mass spectrometry and Western blotting, focusing on human proteins structurally similar to HU1.
Key Results
The study revealed that anti-HU1 antibodies are a significant marker for SLE and LN. Approximately 47% of SLE patients tested positive for anti-HU1, a significantly higher prevalence than in RA, pSS, or healthy control groups.
Key findings include:
- Clinical Correlation: Elevated anti-HU1 levels strongly correlated with the presence of Lupus Nephritis and increased proteinuria, a hallmark of kidney damage.
- In Vivo Aggravation: HU1-immunized mice exhibited more severe kidney pathology, including membrane thickening and increased immune complex deposition.
- Molecular Mimicry and Enzymatic Inhibition: The anti-HU1 antibodies cross-react with human P4HB (Protein Disulfide Isomerase), an enzyme critical for protein folding and cell signaling. Functional assays demonstrated that these antibodies inhibit P4HB's reductase activity in a dose-dependent manner, disrupting renal cell homeostasis.
Discussion
This research highlights a "double-edged sword" immune response. While anti-HU1 antibodies can reduce bacterial biofilm formation, they simultaneously aggravate renal damage by attacking P4HB. This molecular mimicry provides a clear link between common bacterial exposures and the progression of autoimmune kidney disease.
The high specificity of anti-HU1 for SLE suggests its potential as a diagnostic biomarker for renal risk. However, the study is limited by its correlative nature in humans and the fact that 53% of SLE patients do not possess these specific antibodies, indicating other triggers are also at play. Future work should focus on the downstream signaling pathways—potentially involving ADAM17—and explore therapeutic strategies to protect P4HB or mask the HU1 epitope to mitigate kidney damage.
Summary updated